Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Mediwound ( (MDWD) ).
On April 2, 2026, MediWound reported that its North American partner Vericel secured a ten-year BARDA contract, effective April 1, 2026, valued at up to $197 million for NexoBrid. The base $35 million portion includes about $10 million over the next year for initial NexoBrid procurement for the U.S. Strategic National Stockpile and for establishing a vendor-managed inventory system, as well as funds for early development toward a blast trauma indication.
According to Vericel, the agreement also provides options for additional NexoBrid stockpile purchases, expanded clinical work on blast trauma, design and validation of a potential U.S. manufacturing site, and development of a room-temperature-stable formulation. The award deepens NexoBrid’s role in U.S. burn and trauma preparedness and underscores MediWound’s strategic positioning in government-funded emergency stockpiles, with potential long-term benefits for demand, manufacturing scale, and product lifecycle extension.
The most recent analyst rating on (MDWD) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
The score is held down primarily by weak financial performance (shrinking/volatile revenue, large losses, and sustained negative free cash flow) and a technically weak price trend (below key moving averages with negative MACD). The earnings call provides a partial offset via reaffirmed multiyear guidance, manufacturing expansion and trial progress, but execution, funding, and regulatory timing risks remain meaningful; valuation is also constrained by ongoing losses and no dividend yield data.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is a global biotechnology company specializing in next-generation enzymatic, non-surgical therapies for tissue repair. Its lead FDA-approved biologic, NexoBrid, is used for enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan and over 40 countries, while its late-stage pipeline includes EscharEx for chronic wound debridement.
Average Trading Volume: 100,599
Technical Sentiment Signal: Sell
Current Market Cap: $208.1M
For detailed information about MDWD stock, go to TipRanks’ Stock Analysis page.